Lilly to Expand Omvoh for Pediatric Ulcerative Colitis (LLY)

Lilly to expand Omvoh for pediatric ulcerative colitis (LLY)

Eli Lilly (LLY) plans to seek Omvoh label expansion in pediatric ulcerative colitis after positive data from the Phase 3 SHINE-2 trial. Read more here.

Lilly's Omvoh (mirikizumab-mrkz) meets primary endpoint of clinical remission and is the first IL-23p19 inhibitor to report one-year Phase 3 results in pediatric ulcerative colitis

Building on Omvoh's approved use and durable efficacy in adults, Lilly plans to submit these data to global regulators to support a potential label expansion for pediatric ulcerative colitis

Eli Lilly and Company's Omvoh meets pediatric UC endpoint

Half of induction responders were in remission at one year in the uncontrolled Phase 3 study; Lilly plans global regulatory submissions.